Pharma Sector
Latest news, explainers and analysis on Pharma Sector. Tracking 9 stories on Arth Vani.
Connected in the graph
Latest on Pharma Sector
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.
BreakingEli Lilly to Launch Four New Weight-Loss Drugs, Sees Potential in Indian Biotech Despite Funding Lag
Pharmaceutical giant Eli Lilly, driven by the success of Mounjaro and Zepbound, aims to launch up to four new weight-loss products in the coming years. The company acknowledges India's strong biotechnology talent and expertise, but highlights existing challenges in the research funding environment. Eli Lilly has expressed openness to forming partnerships with Indian biotech firms for future collaborations.
Univest's Nifty Pharma Prediction for 2026: What Investors Should Know
Financial research firm Univest has released a long-term prediction for the Nifty Pharma index, targeting September 10, 2026. While the specific forecast details are currently unavailable, this signals Univest's outlook on India's vital pharmaceutical sector and underscores the importance of thorough analysis for investors.
Global Dividend Investing: Why Energy & Pharma Stocks Attract Investors
This report explores the general appeal of high-dividend stocks in the energy and pharmaceutical sectors for investors seeking income, referencing a global source title about a 3% yield. While specific company details from the original content are unavailable, it outlines key considerations for Indian retail investors interested in such opportunities globally.
Beyond Generics: Why Indian Pharma’s Shift to Innovation Offers Long-Term Value
The Indian pharmaceutical sector is moving away from low-margin generic drugs toward high-value innovation and advanced R&D. While the stock market has yet to fully price in this transformation, emerging opportunities in GLP-1 drugs and global supply chain shifts suggest significant growth potential through 2035.
Nifty Eyes 25,500 Recovery: Market Expert Bets on Smallcaps and Pharma
Market veteran Gautam Shah predicts a positive shift for Indian equities, with the Nifty 50 potentially reaching the 25,500 mark. The outlook suggests a pivot towards smallcap stocks, healthcare, and the Adani Group as the broader bull market remains intact.
Dr Reddy’s Shares Dip: What the Downturn Means for Your Pharma Portfolio
Shares of Dr. Reddy's Laboratories faced a decline today, reflecting a broader cooling off in pharmaceutical returns. Retail investors should monitor this Nifty 50 heavyweight as sector-specific volatility impacts both direct holdings and mutual fund NAVs.
Small and Midcap Correction Over: Porinju Veliyath Names Thomas Cook as New Bet
Veteran investor Porinju Veliyath believes the recent downturn in small and midcap stocks has bottomed out, offering a fresh entry point for retail investors. He has recently added Thomas Cook India to his portfolio while highlighting IT and pharma as long-term winners.
Sun Pharma Stock Moves: Assessing India’s Largest Drugmaker Amid Market Fluctuations
Sun Pharmaceutical Industries is seeing active trading as a key Nifty 50 constituent. As India's top drugmaker, its performance remains a crucial indicator for retail investors and those holding pharma-sector mutual funds.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.